BACKGROUND: The mean time in target range for each centre, cTTR, has previously been shown to correlate to the rate of complications in poorly managed @entity1229 treatment. However less is known about the correlation when @entity1229 treatment is well managed. OBJECTIVES: The aim of this study was to examine the correlation between cTTR and the rate of complications in a real life setting with cTTR above 70%, with focus on @entity1 with @entity1229 due to @entity955 or secondary prevention of a VTE. @entity1 /METHODS: In total 66,605 @entity1 with 89,293 treatment periods, corresponding to 179,624treatmentyears, with @entity1229 treatment due to VTE or AF between January 1st 2006 and December 31th 2011, was retrieved from the national quality register AuriculA. The cohort was matched with the National @entity1 Register in Sweden for complications and background characteristics. RESULTS: We found 172 centres and 68,797 treatment periods for AF and 166 centres and 20,496 treatment periods for VTE. Over 90% of the @entity1 had a target range between INR 2-3. We found no correlation between increasing cTTR and reduction in the rate of complications for the AF @entity1 . However, for VTE @entity1 we saw a correlation between increasing cTTR and a reduced complication rate. CONCLUSIONS: Our results show that at very high cTTR levels, above 70%, further improvements in cTTR do not correlate to @entity532 at least for @entity1 with AF.

XXXX treatment complications do not correlate to cTTR when above 70.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS', 'Patient'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation'] @entity532 :: ('MESH:D003925', 'Disease') :: ['less treatment complications'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']
@entity1229 :: (MESH:D014859,Chemical) :: ['Warfarin']
